Dogwood Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Dogwood Therapeutics, Inc. (DWTX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$649.20 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$360.32K.
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$288.89K.
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $377.56K, a 65.79% decline year-over-year.
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $227.66K.
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $208.69K, a 58.16% decline from fiscal 2024.
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $498.72K.
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$490.27K.
- Dogwood Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$429.74K, a 571.53% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$360.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$649.20K 10-Q · filed 2026-08-14 | -$271.64K derived: sum of 3 quarters · filed 2026-08-14 | -$43.99K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$288.89K 10-Q · filed 2026-05-15 | $88.67K derived: sum of 2 quarters · filed 2026-05-15 | $316.33K derived: sum of 3 quarters · filed 2026-05-15 | -$8.39K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $377.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $605.22K derived: sum of 2 quarters · filed 2026-03-18 | $280.50K derived: sum of 3 quarters · filed 2026-08-14 | $208.69K 10-K · filed 2026-03-18 |
| 2025-09-30 | $227.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$97.06K derived: sum of 2 quarters · filed 2026-08-14 | -$168.87K 10-Q · filed 2025-11-07 | $934.91K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$324.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$396.53K 10-Q · filed 2026-08-14 | $707.25K derived: sum of 3 quarters · filed 2026-08-14 | $334.98K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$71.81K 10-Q · filed 2026-05-15 | $1.03M derived: sum of 2 quarters · filed 2026-05-15 | $659.70K derived: sum of 3 quarters · filed 2026-05-15 | $430.33K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $731.51K derived: sum of 2 quarters · filed 2026-03-18 | $502.13K derived: sum of 3 quarters · filed 2026-03-18 | $498.72K 10-K · filed 2026-03-18 |
| 2024-09-30 | -$372.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$601.65K derived: sum of 2 quarters · filed 2025-11-07 | -$605.07K 10-Q · filed 2025-11-07 | -$219.36K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$229.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$232.79K 10-Q · filed 2025-08-13 | $152.92K derived: sum of 3 quarters · filed 2025-08-13 | -$6.29K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$3.42K 10-Q · filed 2025-05-09 | $382.29K derived: sum of 2 quarters · filed 2025-05-09 | $223.09K derived: sum of 3 quarters · filed 2025-05-09 | -$343.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $385.71K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $226.50K derived: sum of 2 quarters · filed 2025-03-31 | -$339.58K derived: sum of 3 quarters · filed 2025-03-31 | -$490.27K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$159.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$725.29K derived: sum of 2 quarters · filed 2024-11-08 | -$875.98K 10-Q · filed 2024-11-08 | -$606.79K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$566.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$716.77K 10-Q · filed 2024-08-09 | -$447.59K derived: sum of 3 quarters · filed 2024-08-09 | -$723.06K derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$150.69K 10-Q · filed 2024-05-10 | $118.50K derived: sum of 2 quarters · filed 2024-05-10 | -$156.98K derived: sum of 3 quarters · filed 2024-05-10 | -$9.62K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $269.18K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | -$6.29K derived: sum of 2 quarters · filed 2024-03-08 | $141.07K derived: sum of 3 quarters · filed 2024-03-08 | -$429.74K 10-K/A · filed 2024-03-08 |
| 2022-09-30 | -$275.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$128.11K derived: sum of 2 quarters · filed 2023-11-13 | -$698.92K 10-Q · filed 2023-11-13 | $148.67K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $147.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$423.45K 10-Q · filed 2023-08-11 | $424.14K derived: sum of 3 quarters · filed 2023-08-11 | -$584.63K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$570.81K 10-Q · filed 2023-05-12 | $276.78K derived: sum of 2 quarters · filed 2023-05-12 | -$732.00K derived: sum of 3 quarters · filed 2023-05-12 | -$2.49M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $847.59K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$161.19K derived: sum of 2 quarters · filed 2023-03-14 | -$1.92M derived: sum of 3 quarters · filed 2023-03-14 | $91.14K 10-K · filed 2023-03-14 |
| 2021-09-30 | -$1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.77M derived: sum of 2 quarters · filed 2022-11-14 | -$756.45K 10-Q · filed 2022-11-14 | $859.90K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $252.32K 10-Q · filed 2022-08-12 | $1.87M derived: sum of 3 quarters · filed 2022-08-12 | $1.77M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $2.01M 10-Q · filed 2022-05-13 | $3.63M derived: sum of 2 quarters · filed 2022-05-13 | $3.52M derived: sum of 3 quarters · filed 2022-05-13 | $3.66M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $1.51M derived: sum of 2 quarters · filed 2022-03-18 | $1.65M derived: sum of 3 quarters · filed 2022-03-18 | $1.66M 10-K · filed 2022-03-18 |
| 2020-09-30 | -$103.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $33.07K derived: sum of 2 quarters · filed 2021-11-12 | $39.48K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $136.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $142.49K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $6.40K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |